Pulmatrix, Inc. discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States.The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology. Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis, and in patients with cystic fibrosis, is in Phase 1b clinical trials.
